IMUX Stock Analysis: Buy, Sell, or Hold?
IMUX - Immunic, Inc. Common Stock
$14.95
0.31 (2.12%)
▲
5d:
-2.67%
30d:
+14.38%
90d:
+1125.41%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When IMUX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called IMUX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IMUX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: IMUX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: IMUX is currently trading at $14.95, which is considered slightly high relative to its 30-day fair value range of $13.23 to $15.33.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $11.70, while resistance sits at $15.77.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+205.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMUX is in a strong uptrend. Immediate support is located at $11.70, while resistance sits at $15.77.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $44.67 (+205.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$13.23 -
$15.33
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 205.1% below Wall St target ($44.67)
Trading Range Analysis
30-Day Trading Range
$13.23 -
$15.33
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$2.14
(14.3%)
Support & Resistance Levels
Support Level
$11.70
Resistance Level
$15.77
Current Trend
Strong Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.13
Wall Street Target
$44.67
(+205.1%)
Share & Embed Analysis
Last updated: July 14, 2026 10:41 AM ET
Data refreshes hourly during market hours. Next update: 11:41 AM
Data refreshes hourly during market hours. Next update: 11:41 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMUX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
|
ORIC
Oric Pharmaceuticals Inc |
STRONG BUY
12 analysts |
$20 | 63 BUY |
